The influence of MDR1 G2677T/A genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers

Pharmacology

Volumn 89, Issue 1-2, 2012, Pages 105-110

  Xiang, Qian ^a   Cui, Yi Min ^a   Zhao, Xia ^a   Yan, Liang ^a   Zhou, Ying ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Chinese; Genetic polymorphism; MDR1; OATP1B1; Repaglinide

Indexed keywords

REPAGLINIDE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; GENE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MDR 1 GENE; NORMAL HUMAN; PHARMACOGENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADULT; ALLELES; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMATES; CYTOCHROME P-450 CYP3A; GENOTYPE; HAPLOTYPES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84862803165     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000336345     Document Type: Article

References (24)

1. Hatorp V: Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41: 471-483.
2. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, Neuvonen PJ: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77: 468-478.
3. He J, Qiu Z, Li N, Yu Y, Lu Y, Han D, Li T, Zhao D, Sun W, Fang F, Zheng J, Fan H, Chen X: Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol 2011; 67: 701-707.
4. Kim EY, Cho DY, Shin HJ, Lee SS, Shon JH, Shin JG, Shin SG: Duplex pyrosequencing assay of the 388A 1 G and 521T 1 C SLCO1B1 polymorphisms in three Asian populations. Clin Chim Acta 2008; 388: 68-72.
5. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ: Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003; 74: 380-387.
6. Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, Stingl JC: Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 2011; 39: 927-932.
7. Ruzilawati AB, Gan SH: CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics. Pharmacology 2010; 85: 357-364.
8. Zhou SF: Structure, function and regulation of P-glycoprotein and its clinical releVance in drug disposition. Xenobiotica 2008; 38: 802-832.
9. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
10. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K: Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-1143.
11. Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, Shen Y, Zhang M, Zheng S: MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 2007; 96: 62-68.
12. Miao LY, Huang CR, Hou JQ, Qian MY: Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2008; 29: 1-5.
13. Kang YS, Park SY, Yim CH, Kwak HS, Gajendrarao P, Krishnamoorthy N, Yun SC, Lee KW, Han KO: The CYP3A4* 18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009; 85: 312-318.
14. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607.
15. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B: Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol 2005; 528: 27-36.
16. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT: Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005; 78: 388-399.
17. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S: Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006; 34: 1976-1984.
18. Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H: The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 2008; 160: 308-315.
19. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ: MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-smallcell lung cancer. Respiration 2009; 78: 49-55.
20. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG: A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 2004; 76: 418-427.
21. Totah RA, Rettie AE: Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical releVance. Clin Pharmacol Ther 2005; 77: 341-352.
22. Saito Y, Katori N, Soyama A, Nakajima Y, Yoshitani T, Kim SR, Fukushima-Uesaka H, Kurose K, Kaniwa N, Ozawa S, Kamatani N, Komamura K, Kamakura S, Kitakaze M, Tomoike H, Sugai K, Minami N, Kimura H, Goto Y, Minami H, Yoshida T, Kunitoh H, Ohe Y, Yamamoto N, Tamura T, Saijo N, Sawada J: CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics 2007; 17: 461-471.
23. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, Liu ZQ, Wang D, Huang YF, Zhou HH, Sun ZQ: Organic anion transporting polypeptide- 1B1 haplotypes in Chinese patients. Acta Pharmacol Sin 2007; 28: 1693-1697.
24. Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y, Yu L, Zhang A, Wang L, Wang H, Li X, Feng G, He L: Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 2006; 7: 831-841.